We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Antidepressants in Pregnancy Increase Risk of Miscarriage

By LabMedica International staff writers
Posted on 07 Jun 2010
A new study has found a 68% increase in the overall risk of miscarriage in pregnant women using antidepressants.

Researchers from the University of Montreal (Canada) and the CHU Ste-Justine (Montreal, Canada) examined data on 5,124 women in Quebec (Canada) from a large population-based cohort of pregnant women who had clinically verified miscarriages at up to 20 weeks of gestation, and a large sample of women from the same registry who did not have a miscarriage. More...
Of those who miscarried, 284 (5.5%) had taken antidepressants during pregnancy.

The researchers found that selective serotonin reuptake inhibitors (SSRIs), especially paroxetine and venlafaxine, were associated with increased risk of miscarriage, as were higher daily doses of either antidepressant; a combination of different antidepressants further doubled the risk of miscarriages. The researchers urged physicians who have patients of childbearing age taking antidepressants, or pregnant patients who require antidepressant therapy early in pregnancy, to discuss the risks and benefits with them. The study was published in the June 2010 issue of the Canadian Medical Association Journal (CMAJ).

"These results, which suggest an overall class effect of selective serotonin reuptake inhibitors, are highly robust given the large number of users studied,” said senior author Anick Bérard, Ph.D., and colleagues of the faculty of pharmacy at the University of Montreal.

SSRIs are typically used in the treatment of depression, anxiety disorders, and some personality disorders. They are also typically effective and used in treating premature ejaculation problems as well as some cases of insomnia. SSRIs increase the extracellular level of the neurotransmitter serotonin by inhibiting its reuptake into the presynaptic cell, increasing the level of serotonin available to bind to the postsynaptic receptor.

Related Links:

University of Montreal
CHU Ste-Justine




Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Urine Analyzer
respons® UDS100
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.